‘
‘
February 20, 2017
‘
<'">
0
introduction to research/chemotherapy can completely destroy cancer cells in the lymph nodes
0
introduction to research/chemotherapy can completely destroy cancer cells in the lymph nodes
Research suggests that neoadjuvant chemotherapy can completely destroy cancer cells in the lymph nodes in 40% to 70% of women. A new type of lymph node surgery, called targeted axillary dissection (TAD), developed at the University of Texas MD Anderson Cancer Center, seems to allow doctors to see which lymph nodes have become cancer-free after neoadjuvant chemotherapy. This means that fewer lymph nodes can be removed. “As chemotherapy is utilized more often before surgery, there is a greater likelihood that the disease in the lymph nodes will be eradicated and surgeons do not need to perform extensive nodal surgery,” we hoped to find a new way to target the lymph node known to have cancer, selectively remove it, look at it, and hopefully avoid additional surgery if chemotherapy has wiped out all the cancer.” ” said Henry Kuerer, M.D., Ph.D., professor of breast surgical oncology at MD Anderson and another paper author. “Our findings epitomize precision surgery in that we are specifically targeting the known disease and limiting the morbidity for our patients.”http://www.breastcancer.org/research-news/new-surgery-may-require-fewer-nodes-removed The success of treatment largely depends on the extent of disease at presentation. Hence, identification of prognostic factors and factors predicting response to specific treatment protocols, epitomize an IMPORTANT area in research. Screening in breast cancer helps to detect disease at an early stage, when chances to achieve cure are high. Small tumours confined to the breast, without micro-metastasis have high chances of cure whereas big tumours which spread to axillary lymph nodes are consistently associated with subclinical systemic spread and strongly predict advanced disease Increasing number of involved axillary lymph nodes is associated with an increased probability of recurrence and mortality axillary lymph node status being the single most important prognostic indication. https://www.ncbi.nlm.nih.gov/pubmed/27504343 The addition of adjuvant chemotherapy to standard breast cancer therapy has been shown to improve outcome substantially (bib10Early Breast Cancer Trialists’ Collaborative Group, 1998). There are several arguments for applying chemotherapy in a so-called neoadjuvant treatment setting, prior to surgery. First, by downstaging the tumour, less extensive resections are needed and breast conservation becomes increasingly feasible (bib27Makris et al, 1998; bib28Mauriac et al, 1999). Second, micrometastases that may be present are thus treated at the earliest possible moment. This could prevent changes in metastatic cells, associated with a worse prognosis: A third advantage of neoadjuvant chemotherapy is that it enables the monitoring of treatment efficacy and makes it possible to identify markers of response to chemotherapy http://www NATURE.com/bjc/journal/v88/n3/full/6600749a.html We demonstrated that, in patients without slnb before completion of nac, axillary restaging adjusted by pcr after completion of neoadjuvant treatment is an independent prognostic factor for breast cancer patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671025/ Primary or neoadjuvant systemic che- motherapy is the standard treatment for pa- tients with locally advanced breast cancer and large, operable breast cancer, who de- sire breast-conserving surgery; it is also being assessed in patients with earlier- stage disease, and other types of cancer.
this is an introduction of 5 articles, i just want you to rephrase it in the same order here:
�
1- breast cancer , incidence of breast cancer *refrence*
�
2- incidence of breast cancer in saudi arabia *refrence*
�
3- axillary node of patient , great impact on patient prognosis and survival *refrence*
�
4- neo adjuvant chemotherapy benefit in breast cancer *refrence*
�
5- neo adjuvant therapy specific impact on axillary nodes *refrence*
�
�
– aim of our study is to address the rple of neo adjuvant chemotherapy , axillary (clinically , radio , patuo)
�
– patient ( before and after the NAC)
�
all you need to do is see the attach file and open each link and rephrase the article into 1 introductin starting with what’s breat cancer and ending with neo adjuvant therapyÂÂÂÂ?
this is a very easy essay , it’s only an introduction that needs to be rephrased
Previous answers to this question
This is a preview of an assignment submitted on our website by a student. If you need help with this question or any assignment help, click on the order button below and get started. We guarantee authentic, quality, 100% plagiarism free work or your money back.
Get The Answer introduction to research/chemotherapy can completely destroy cancer cells in the lymph nodes
‘
‘
February 20, 2017
‘
<'">
0
introduction to research/chemotherapy can completely destroy cancer cells in the lymph nodes
Research suggests that neoadjuvant chemotherapy can completely destroy cancer cells in the lymph nodes in 40% to 70% of women. A new type of lymph node surgery, called targeted axillary dissection (TAD), developed at the University of Texas MD Anderson Cancer Center, seems to allow doctors to see which lymph nodes have become cancer-free after neoadjuvant chemotherapy. This means that fewer lymph nodes can be removed. “As chemotherapy is utilized more often before surgery, there is a greater likelihood that the disease in the lymph nodes will be eradicated and surgeons do not need to perform extensive nodal surgery,” we hoped to find a new way to target the lymph node known to have cancer, selectively remove it, look at it, and hopefully avoid additional surgery if chemotherapy has wiped out all the cancer.” ” said Henry Kuerer, M.D., Ph.D., professor of breast surgical oncology at MD Anderson and another paper author. “Our findings epitomize precision surgery in that we are specifically targeting the known disease and limiting the morbidity for our patients.”http://www.breastcancer.org/research-news/new-surgery-may-require-fewer-nodes-removed The success of treatment largely depends on the extent of disease at presentation. Hence, identification of prognostic factors and factors predicting response to specific treatment protocols, epitomize an IMPORTANT area in research. Screening in breast cancer helps to detect disease at an early stage, when chances to achieve cure are high. Small tumours confined to the breast, without micro-metastasis have high chances of cure whereas big tumours which spread to axillary lymph nodes are consistently associated with subclinical systemic spread and strongly predict advanced disease Increasing number of involved axillary lymph nodes is associated with an increased probability of recurrence and mortality axillary lymph node status being the single most important prognostic indication. https://www.ncbi.nlm.nih.gov/pubmed/27504343 The addition of adjuvant chemotherapy to standard breast cancer therapy has been shown to improve outcome substantially (bib10Early Breast Cancer Trialists’ Collaborative Group, 1998). There are several arguments for applying chemotherapy in a so-called neoadjuvant treatment setting, prior to surgery. First, by downstaging the tumour, less extensive resections are needed and breast conservation becomes increasingly feasible (bib27Makris et al, 1998; bib28Mauriac et al, 1999). Second, micrometastases that may be present are thus treated at the earliest possible moment. This could prevent changes in metastatic cells, associated with a worse prognosis: A third advantage of neoadjuvant chemotherapy is that it enables the monitoring of treatment efficacy and makes it possible to identify markers of response to chemotherapy http://www NATURE.com/bjc/journal/v88/n3/full/6600749a.html We demonstrated that, in patients without slnb before completion of nac, axillary restaging adjusted by pcr after completion of neoadjuvant treatment is an independent prognostic factor for breast cancer patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671025/ Primary or neoadjuvant systemic che- motherapy is the standard treatment for pa- tients with locally advanced breast cancer and large, operable breast cancer, who de- sire breast-conserving surgery; it is also being assessed in patients with earlier- stage disease, and other types of cancer.
this is an introduction of 5 articles, i just want you to rephrase it in the same order here:
�
1- breast cancer , incidence of breast cancer *refrence*
�
2- incidence of breast cancer in saudi arabia *refrence*
�
3- axillary node of patient , great impact on patient prognosis and survival *refrence*
�
4- neo adjuvant chemotherapy benefit in breast cancer *refrence*
�
5- neo adjuvant therapy specific impact on axillary nodes *refrence*
�
�
– aim of our study is to address the rple of neo adjuvant chemotherapy , axillary (clinically , radio , patuo)
�
– patient ( before and after the NAC)
�
all you need to do is see the attach file and open each link and rephrase the article into 1 introductin starting with what’s breat cancer and ending with neo adjuvant therapyÂÂÂÂ?
this is a very easy essay , it’s only an introduction that needs to be rephrased